RTW Biotech Opportunities invests $275 million in Encoded Therapeutics
RTW Biotech Opportunities Ltd says it is arranging a $275 million financing to advance ETX101 through pivotal development in Dravet syndrome.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.